AUG 03, 2015 11:05 PM PDT

Melanoma's Modus Operandi

WRITTEN BY: Ilene Schneider
Why does melanoma, which accounts for 2 percent of skin cancer cases, cause almost all skin cancer deaths? Why have melanoma rates in the US been rising rapidly over the last 30 years? What is melanoma's modus operandi?
Israeli researchers have unlocked puzzling trigger of melanoma.
A new study at Tel Aviv University (TAU), published in Molecular Cell and reported in Drug Discovery & Development, offers insight into the exact trigger that causes melanoma cancer cells to transform from non-invasive cells to invasive killer agents, showing the exact place in the process where "traveling" cancer turns deadly. Dr. Carmit Levy of the Department of Human Genetics and Biochemistry at TAU's Sackler School of Medicine led the study, which was conducted by a team of researchers from TAU, the Technion Institute of Technology, the Sheba Medical Center, the Institut Gustave Roussy and The Hebrew University of Jerusalem
(http://www.dddmag.com/news/2015/08/researcher-discovers-trigger-deadly-melanoma?et_cid=4710740&et_rid=45505806&location=top).

According to skincancer.org, melanoma is the most dangerous form of skin cancer. Cancerous growths develop when unrepaired DNA damage to skin cells triggers mutations (genetic defects) that cause the skin cells to multiply quickly and form malignant tumors that originate in the pigment-producing melanocytes in the basal layer of the epidermis. Melanomas, which look like moles, sometimes develop from moles. Most are black or brown, but they can also be flesh-colored, pink, red, purple, blue or white. Melanoma, which is caused mostly by intense, occasional UV exposure, especially in those who are genetically predisposed to the disease, kills an estimated 9,940 people in the US annually
(http://www.skincancer.org/skin-cancer-information/melanoma).

Melanoma that is caught in time can be removed and the patient's life saved, but if it invades the bloodstream, turning metastatic, the treatment is aggressive and not always successful. Dr. Levy wanted to know when and how the transformation into aggressive invasion took place. As he explained, "To understand melanoma, I had to obtain a deep understanding about the structure and function of normal skin. Melanoma is a cancer that originates in the epidermis, and in its aggressive form it will invade the dermis, a lower layer, where it eventually invades the bloodstream or lymph vessels, causing metastasis in other organs of the body. But before invading the dermis, melanoma cells surprisingly extend upward, then switch directions to invade. It occurred to me that there had to be a trigger in the microenvironment of the skin that made the melanoma cells 'invasive.' Using the evolutionary logic of the tumor, why spend the energy going up when you can just use your energy to go down and become malignant?"

The researchers collected samples of normal skin cells and melanoma cells from patients at hospitals around Israel, mixed normal and cancerous cells and performed gene analysis expression to study the traveling cancer's behavior. They discovered that, completely independently of any mutation acquisition, the microenvironment alone was the trigger for melanoma metastasis.

According to Dr. Levy "Normal skin cells are not supposed to 'travel.' We found that when melanoma is situated at the top layer, a trigger sends it down to the dermis and then further down to invade blood vessels. If we could stop it at the top layer, block it from invading the bloodstream, we could stop the progression of the cancer."

The researchers discovered that the direct contact of melanoma cells with the remote epidermal layer triggered an invasion by activating "Notch signaling," which activates a set of genes that stimulates changes in melanoma cells, making them invasive. They found that when a molecule expressed on a cell membrane - a spike on the surface of a cell, called a ligand - comes into contact with a melanoma cell, it transforms the cell into an invasive, deadly agent.

Dr. Levy concluded, "Melanoma is a cancer with a very long gestation period. If you can provide a simple kit with precise answers, you can catch it at the beginning stage and hopefully save lives."
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
MAR 23, 2020
Cancer
MAR 23, 2020
An Alternative Use for Common Kidney Cancer Drug to Fight Against Epithelial Ovarian Cancer
Axitinib is a small molecule drug that inhibits VEGFR tyrosine kinases 1, 2, and 3. Shown previously to potentially prev ...
APR 08, 2020
Cancer
APR 08, 2020
Changing cell pH to block pancreatic cancer
New research published in Cancer Discovery suggests that manipulating the pH of pancreatic cancer cells can deter cell g ...
APR 09, 2020
Cancer
APR 09, 2020
Adjuvant immunotherapy proves effective for colon cancer
Results from a study published in Nature Medicine highlights the benefits of receiving pre-surgery immunotherapy for som ...
APR 17, 2020
Drug Discovery & Development
APR 17, 2020
Overcoming Multi-Drug Resistance in Cancer
Resistance to chemotherapeutic use in caner patients is something that is inevitable. Continued resistance to these drug ...
MAY 02, 2020
Cancer
MAY 02, 2020
Tracking DNA Methylation as a Prognostic Marker
In the modern age of biological research, one of the tools that have become readily available in the ever-increasing dat ...
MAY 01, 2020
Cancer
MAY 01, 2020
Cancer patients' high mortality from COVID-19
A study published today in the online edition of Cancer Discovery reports that people with cancer who develop COVID-19 a ...
Loading Comments...